<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03602898</url>
  </required_header>
  <id_info>
    <org_study_id>9954</org_study_id>
    <secondary_id>NCI-2018-01302</secondary_id>
    <secondary_id>9954</secondary_id>
    <secondary_id>RG1001747</secondary_id>
    <nct_id>NCT03602898</nct_id>
  </id_info>
  <brief_title>Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation</brief_title>
  <official_title>A Randomized Phase II Study to Compare ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well 3 different drug combinations prevent graft versus host&#xD;
      disease (GVHD) after donor stem cell transplant. Calcineurin inhibitors, such as cyclosporine&#xD;
      and tacrolimus, may stop the activity of donor cells that can cause GVHD. Chemotherapy drugs,&#xD;
      such as cyclophosphamide and methotrexate, may also stop the donor cells that can lead to&#xD;
      GVHD while not affecting the cancer-fighting donor cells. Immunosuppressive therapy, such as&#xD;
      anti-thymocyte globulin (ATG), is used to decrease the body's immune response and reduces the&#xD;
      risk of GVHD. It is not yet known which combination of drugs: 1) ATG, methotrexate, and&#xD;
      calcineurin inhibitor 2) cyclophosphamide and calcineurin inhibitor, or 3) methotrexate and&#xD;
      calcineurin inhibitor may work best to prevent graft versus host disease and result in best&#xD;
      overall outcome after donor stem cell transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:&#xD;
&#xD;
      CONDITIONING REGIMENS: Participants receive 1 of 3 regimens and are randomized to 1 of 3 arms&#xD;
      for GVHD prophylaxis.&#xD;
&#xD;
      REGIMEN A: Participants undergo total body irradiation (TBI) twice daily (BID) on days -6 to&#xD;
      -4 (-7 to -4 for those &lt; 18 years), then receive cyclophosphamide IV over 1-2 hours on days&#xD;
      -3 and -2. Participants randomized to Arm 2 only receive TBI on days -3 to -1 (-4 to -1 for&#xD;
      those &lt; 18 years).&#xD;
&#xD;
      REGIMEN B: Participants receive fludarabine phosphate IV and busulfan IV every 6 hours on&#xD;
      days -5 to -2.&#xD;
&#xD;
      REGIMEN C: Participants receive busulfan orally (PO) or IV every 6 hours on days -7 to -4 and&#xD;
      cyclophosphamide IV over 1-2 hours on days -3 and -2.&#xD;
&#xD;
      Myelofibrosis or other myeloproliferative neoplasms: Participants &gt;= 18 years receive&#xD;
      cyclophosphamide IV over 1-2 hours on days -7 and -6 and busulfan IV on days -5 to -2.&#xD;
      Participants &lt; 17 years receive busulfan IV every 6 hours on days -7 to -4 and&#xD;
      cyclophosphamide IV on days -3 and -2.&#xD;
&#xD;
      All participants undergo peripheral blood stem cell transplantation on day 0.&#xD;
&#xD;
      ARM 1: Participants receive anti-thymocyte globulin IV over 4-6 hours on days -3 to -1.&#xD;
      Beginning day -1, participants also receive tacrolimus IV or cyclosporine IV twice daily&#xD;
      (BID) tapered at day 50, and methotrexate IV on days 1, 3, 6 and 11 in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      ARM 2: Participants receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Beginning day&#xD;
      5, participants also receive tacrolimus IV or cyclosporine IV BID tapered at day 50 in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      ARM 3: Beginning day -1, participants receive tacrolimus IV or cyclosporine IV BID tapered at&#xD;
      day 50, and methotrexate IV on days 1, 3, 6 and 11 in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, participants are followed up at 6 months, then annually&#xD;
      up to 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Insufficient funding&#xD;
  </why_stopped>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">September 17, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 17, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Moderate to severe chronic graft versus host disease (GVHD) based on National Institute of Health 2014 consensus criteria</measure>
    <time_frame>At 1 year</time_frame>
    <description>Probabilities of chronic GVHD at one year will be compared using a chi-square test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>At 1 year post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVHD-free relapse-free survival (GRFS)</measure>
    <time_frame>At 1 year post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic GVHD-free relapse-free survival (CRFS)</measure>
    <time_frame>At 1 year post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade II-IV acute GVHD</measure>
    <time_frame>At 100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade III-IV acute GVHD</measure>
    <time_frame>At 100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>At 1 year post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>At 1 year post transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Hematopoietic and Lymphoid System Neoplasm</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myelofibrosis</condition>
  <condition>Myeloproliferative Neoplasm</condition>
  <condition>Recurrent Acute Myeloid Leukemia</condition>
  <condition>Recurrent Hodgkin Lymphoma</condition>
  <condition>Recurrent Non-Hodgkin Lymphoma</condition>
  <condition>Refractory Acute Myeloid Leukemia</condition>
  <condition>Therapy-Related Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Participants receive anti-thymocyte globulin IV over 4-6 hours on days -3 to -1. Beginning day -1, participants also receive tacrolimus IV or cyclosporine IV BID tapered at day 50, and methotrexate IV on days 1, 3, 6 and 11 in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Participants receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Beginning day 5, participants also receive tacrolimus IV or cyclosporine IV BID tapered at day 50 in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 (tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Beginning day -1, participants receive tacrolimus IV or cyclosporine IV BID tapered at day 50, and methotrexate IV on days 1, 3, 6 and 11.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-Thymocyte Globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <other_name>Antithymocyte Globulin</other_name>
    <other_name>Antithymocyte Serum</other_name>
    <other_name>ATG</other_name>
    <other_name>ATS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <arm_group_label>Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)</arm_group_label>
    <arm_group_label>Arm 3 (tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <other_name>1, 4-Bis[methanesulfonoxy]butane</other_name>
    <other_name>BUS</other_name>
    <other_name>Bussulfam</other_name>
    <other_name>Busulfanum</other_name>
    <other_name>Busulfex</other_name>
    <other_name>Busulphan</other_name>
    <other_name>CB 2041</other_name>
    <other_name>CB-2041</other_name>
    <other_name>Glyzophrol</other_name>
    <other_name>GT 41</other_name>
    <other_name>GT-41</other_name>
    <other_name>Joacamine</other_name>
    <other_name>Methanesulfonic Acid Tetramethylene Ester</other_name>
    <other_name>Methanesulfonic acid, tetramethylene ester</other_name>
    <other_name>Mielucin</other_name>
    <other_name>Misulban</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeleukon</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Myelosan</other_name>
    <other_name>Mylecytan</other_name>
    <other_name>Myleran</other_name>
    <other_name>Sulfabutin</other_name>
    <other_name>Tetramethylene Bis(methanesulfonate)</other_name>
    <other_name>Tetramethylene bis[methanesulfonate]</other_name>
    <other_name>WR-19508</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <arm_group_label>Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)</arm_group_label>
    <arm_group_label>Arm 3 (tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <arm_group_label>Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)</arm_group_label>
    <arm_group_label>Arm 3 (tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <other_name>27-400</other_name>
    <other_name>Ciclosporin</other_name>
    <other_name>CsA</other_name>
    <other_name>Cyclosporin</other_name>
    <other_name>Cyclosporin A</other_name>
    <other_name>Gengraf</other_name>
    <other_name>Neoral</other_name>
    <other_name>OL 27-400</other_name>
    <other_name>Sandimmune</other_name>
    <other_name>SangCya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <arm_group_label>Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)</arm_group_label>
    <arm_group_label>Arm 3 (tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <arm_group_label>Arm 3 (tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo peripheral blood stem cell transplantation</description>
    <arm_group_label>Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <arm_group_label>Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)</arm_group_label>
    <arm_group_label>Arm 3 (tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSCT</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <arm_group_label>Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)</arm_group_label>
    <arm_group_label>Arm 3 (tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <arm_group_label>Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)</arm_group_label>
    <arm_group_label>Arm 3 (tacrolimus or cyclosporine, methotrexate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <arm_group_label>Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)</arm_group_label>
    <arm_group_label>Arm 3 (tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <arm_group_label>Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)</arm_group_label>
    <arm_group_label>Arm 3 (tacrolimus or cyclosporine, methotrexate)</arm_group_label>
    <other_name>Total Body Irradiation</other_name>
    <other_name>whole body irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
    <other_name>TBI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The following diseases will be permitted, although other diagnoses can be considered&#xD;
             if approved by Fred Hutch Patient Care Conference or the participating institution's&#xD;
             patient review committees and the principal investigator:&#xD;
&#xD;
               -  Acute lymphocytic leukemia (ALL) in complete remission (CR)1 with high risk&#xD;
                  features defined as evidence of adverse cytogenetics such as t(9;22), t(1;19),&#xD;
                  t(4;11), or MLL rearrangements or presence of minimal residual disease&#xD;
&#xD;
               -  Acute myeloid leukemia (AML) in CR1 with high risk features defined as:&#xD;
&#xD;
                    -  Intermediate or adverse risk disease as defined by European LeukemiaNet&#xD;
                       (ELN) 2017&#xD;
&#xD;
                    -  Greater than 1 cycle of induction therapy required to achieve remission&#xD;
&#xD;
                    -  Preceding myelodysplastic syndrome (MDS) or myelofibrosis&#xD;
&#xD;
                    -  Therapy-related AML&#xD;
&#xD;
                    -  Presence of FLT3 internal tandem duplications&#xD;
&#xD;
                    -  French-American-British (FAB) M6 or M7 classification&#xD;
&#xD;
               -  Acute leukemia (ALL or AML) in second (2nd) or greater CR (CR â‰¥ 2)&#xD;
&#xD;
               -  Refractory or relapsed AML with =&lt; 5% bone marrow blasts and no circulating&#xD;
                  blasts by morphology or proven extramedullary disease&#xD;
&#xD;
               -  Myelodysplastic syndrome (MDS) with following high risk features: poor&#xD;
                  cytogenetics (-7, inv(3)/t(3q)/del(3q), del(7q) or complex cytogenetics defined&#xD;
                  as &gt;= 3 abnormalities), Revised International Prognostic Scoring System (IPSS-R)&#xD;
                  risk group intermediate or higher, or treatment-related MDS&#xD;
&#xD;
               -  Any phase of MDS if patient is &lt; 21 years of age&#xD;
&#xD;
               -  Chronic myelogenous leukemia (CML) beyond 1st chronic phase or resistant to&#xD;
                  tyrosine kinase inhibitors (adults)&#xD;
&#xD;
               -  Chronic myelomonocytic leukemia (CMML)&#xD;
&#xD;
               -  Myeloproliferative disorders/myelofibrosis&#xD;
&#xD;
               -  Hodgkin or non-Hodgkin lymphoma: relapsed chemotherapy-sensitive (complete or&#xD;
                  partial response)&#xD;
&#xD;
          -  Female patients must have negative standard pregnancy test (all women of child&#xD;
             bearing-potential must have test performed)&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
          -  For patients with acute leukemia, CR is defined as =&lt; 5% marrow blasts by morphology.&#xD;
             CR with incomplete count recovery is allowed&#xD;
&#xD;
          -  DONOR INCLUSION&#xD;
&#xD;
          -  Unrelated donors matched for human leukocyte antigen (HLA)-A, B, C, DRB1 and DQB1 by&#xD;
             high resolution typing&#xD;
&#xD;
          -  Donors are excluded when preexisting immunoreactivity is identified that would&#xD;
             jeopardize donor hematopoietic cell engraftment. This determination is based on the&#xD;
             standard practice of the individual institution. The recommended procedure for&#xD;
             patients with 10 of 10 HLA allele level (phenotypic) match is to obtain a panel&#xD;
             reactive antibody (PRA) screens to class I and class II antigens for all patients&#xD;
             before hematopoietic cell transplantation (HCT). If the PRA shows &gt; 10% activity, then&#xD;
             flow cytometric or B and T cell cytotoxic cross matches should be obtained. The donor&#xD;
             should be excluded if any of the cytotoxic cross match assays are positive&#xD;
&#xD;
          -  Only granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem&#xD;
             cell (PBSC) will be permitted as a hematopoietic stem cell (HSC) source on this&#xD;
             protocol&#xD;
&#xD;
          -  Donors must meet the selection criteria for administration of G-CSF and apheresis&#xD;
             defined based on each institution's standard practice protocol for unrelated donors&#xD;
&#xD;
          -  Donors must be capable of giving informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior autologous or allogeneic stem cell transplant&#xD;
&#xD;
          -  Performance status: Karnofsky score &lt;60 or Lansky score &lt;50 for patients &lt;16 years old&#xD;
&#xD;
          -  Uncontrolled infection. The protocol principal investigator (PI) will be final arbiter&#xD;
             if there is uncertainty regarding whether a previous infection is under adequate&#xD;
             control to allow enrollment in the study&#xD;
&#xD;
          -  Positive serology for human immunodeficiency virus (HIV)-1, 2 or human T-lymphotropic&#xD;
             virus (HTLV)-1, 2&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 45%. Uncontrolled arrhythmias or symptomatic&#xD;
             cardiac disease&#xD;
&#xD;
          -  Symptomatic pulmonary disease. Forced expiratory volume in 1 second (FEV1), forced&#xD;
             vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLCO) =&lt; 50%&#xD;
             of predicted (corrected for hemoglobin). Use of continuous supplemental oxygen&#xD;
&#xD;
          -  Calculated (Cockroft-Gault; or appropriate calculation for pediatric patients) serum&#xD;
             creatinine clearance &lt;60 mL/min. If the calculated CrCl is 50-60 mL/min, but a&#xD;
             measured CrCl by 24 hour urine collection is &gt; 60 mL/min, this measurement is&#xD;
             acceptable&#xD;
&#xD;
          -  Total serum bilirubin more than twice upper normal limit&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) more than 3-fold&#xD;
             higher than laboratory upper normal limits&#xD;
&#xD;
          -  History of allergy or anaphylactic reaction to rabbit protein or to any product&#xD;
             excipients&#xD;
&#xD;
          -  Subjects may not be enrolled in other investigational trials with acute or chronic&#xD;
             GVHD as the primary endpoint&#xD;
&#xD;
          -  DONOR EXCLUSION&#xD;
&#xD;
          -  Donor who will exclusively donate marrow&#xD;
&#xD;
          -  Donors who are HIV-positive&#xD;
&#xD;
          -  Potential donors who for psychological, physiological, or medical reasons cannot&#xD;
             tolerate administration of G-CSF or apheresis&#xD;
&#xD;
          -  Donors who are allergic to filgrastim or Escherichia (E.) coli-derived proteins&#xD;
&#xD;
          -  Donor-related risks to recipients&#xD;
&#xD;
          -  Positive anti-donor lymphocytotoxic crossmatch&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Prior malignancy within the last 5 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masumi Ueda Oshima</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 13, 2018</study_first_submitted>
  <study_first_submitted_qc>July 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

